Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation

NCT02499237 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: Denosumab
DRUG: Zoledronic acid

Sponsor

424 General Military Hospital

Collaborators

[object Object]
[object Object]